Download PDF
Thromb Haemost 1995; 74(01): 473-481
DOI: 10.1055/s-0038-1642724
Symposium
New Antithrombins
Schattauer GmbH Stuttgart

Comparative Pharmacology of Site Directed Antithrombin Agents. Implication in Drug Development

Demetra Callas
Departments of Pharmacology and Pathology, Loyola University Medical Center, Maywood, IL, USA
,
Jawad Fareed
Departments of Pharmacology and Pathology, Loyola University Medical Center, Maywood, IL, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 De Fouw NJ, van Hinsberg VW, de Jong YF, Haverkate F, Bertina RBertina. he interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 176
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Dichek D, Quertermous T. hrombin regulation of mRNA levels of tissue plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222-228
    PubMedGoogle Scholar
  • 3 Collen D, Lijnen HR, Todd PA, Goa KGoa. issue-type plasminogen activator: A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346-388
    CrossrefPubMedGoogle Scholar
  • 4 Pannell R, Gurewich V. ro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223
    PubMedGoogle Scholar
  • 5 Hoylaerts M, Rijken D, Lijnen HR, Collen D. inetics of the activation of plasminogen by human tissue plasminogen activator, role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 6 Coleman RColeman. ctivation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1968; 35: 273-279
    PubMedGoogle Scholar
  • 7 Goldsmith GH, Saito H, Ratnoff ORatnoff. he activation of plasminogen by Hageman factor fragments. J Clin Invest 1978; 62: 54-60
    CrossrefPubMedGoogle Scholar
  • 8 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DLoskutoff. ctivated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-1125
    CrossrefPubMedGoogle Scholar
  • 9 Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. ibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res 1994; 74 (03) 193-205
    CrossrefPubMedGoogle Scholar
  • 10 Gilboa N, Villannueva Fenton II JW. Inhibition of fibrinolytic enzymes by thrombin inhibitors. Enzyme 1988; 40: 144-148
    CrossrefPubMedGoogle Scholar
  • 11 Barabas E, Szell E, Bajusz S. creening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagulation and Fibrinolysis 1993; 4: 243-248
    CrossrefPubMedGoogle Scholar
  • 12 Bock LC, Griffin LC, Latham JA, Veimaas EH, Toole JToole. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355 6360 564-566
    CrossrefPubMedGoogle Scholar
  • 13 Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J. hrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 1993; 90: 3745-3749
    CrossrefPubMedGoogle Scholar
  • 14 Paborsky LR, McCurdy SN, Griffin LC, Toole JJ, Leung LL K. The single-stranded DNA aptamer binding-site of human thrombin. J Biol Chem 1993; 268: 20808
    PubMedGoogle Scholar
  • 15 Li WX, Kaplan AV, Grant GW, Toole JJ, Leung LL K. A novel nucleotide- based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994; 83 (03) 677-682
    PubMedGoogle Scholar
  • 16 Latham JA, Johnson R, Toole JToole. he application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(l-pentynyl)- 2'-deoxyuridine. Nucleic Acids Research 1994; 22 (14) 2817-2822
    CrossrefPubMedGoogle Scholar
  • 17 Kubik MF, Stephens AW, Schneider D, Marlar R, Tasset D. High-affinity RNA ligands to human a-thrombin. Nucleic Acids Research 1994; 22 (13) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 18 Petersen TE, Roberts HR, Sottrup-Jensen L, Magnusson S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Peptides of the Biological Fluids. Peters H. ed. Pergamon, Oxford; 1976: 145-149
    Google Scholar
  • 19 Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, Lecocq JLecocq. loning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech Hirudo medicinalis:. Proc Natl Acad Sci USA 1986; 83: 1084-1088
    CrossrefPubMedGoogle Scholar
  • 20 Dodt J, Kohler S, Schmitz T, Wilhelm B. istinct binding sites of Ala48-hiradin 1 -47 and Ala48-hiradin48-65 on a thrombin. J Biol Chem 1990; 265: 713-718
    PubMedGoogle Scholar
  • 21 Scharf M, Engels J, Tripier D. rimary structures of new “isohirudins”. FEES Lett 1989; 225: 105-110
    PubMedGoogle Scholar
  • 22 Kurfurst MKurfurst. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate - polyacrylamide gel electrophoresis. Analytical Biochemistry 1992; 200 (02) 244-248
    CrossrefPubMedGoogle Scholar
  • 23 Zawilska K, Zozulinska M, Turowiecka Z, Blahut M, Drobnik L, Vinalzer H. he effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993; 69 (03) 315-320
    CrossrefPubMedGoogle Scholar
  • 24 DiMaio J, Gibbs B, Munn D, Lefebvre J, Ni F, Konishi Y. ifunctional thrombin inhibitors based on the sequence of hirudin. J Biol Chem 1990; 265 (35) 21698-21703
    PubMedGoogle Scholar
  • 25 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JM. esign and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
    CrossrefPubMedGoogle Scholar
  • 26 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. se of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87 (05) 1622-1629
    CrossrefPubMedGoogle Scholar
  • 27 Cannon CP, Maraganore JM, Loscalzo J. nticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71: 778-782
    CrossrefPubMedGoogle Scholar
  • 28 Theroux P, Lidon R. nticoagulants and their use in acute ischemic syndromes. In: Textbook of Interventional Cardiology. Topol EJ. ed. WB Saunders Co; Philadelphia, PA: 1994: 23-45
    Google Scholar
  • 29 Vlasuk G, Vallar PL, Weinhouse MI, Bergum PW, Tran HS, Weitz JI, Tulinsky A, Krishnan R, Rote WE, Oldeschulte GL, Pearson DPearson. novel inhibitor of thrombin containing multiple recognition sequences linked by a-keto amide transition state. Circulation 1994; 90 (04) 1-348
    CrossrefPubMedGoogle Scholar
  • 30 Hijikata-Okunomiya A, Okamoto S. strategy for a rational approach to designing synthetic selective inhibitors. Sem Thromb Hemost 1992; 18 (01) 135-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Tamao Y, Yamamoto T, Kimumoto R, Itoh J, Hirata T, Mineo K, Okamoto S. ffect of a selective thrombin-inhibitor MCI-903 8 on fibrinolysis in vitro and in vivo . Thromb Haemost 1986 562: 28-34
    PubMedGoogle Scholar
  • 32 Tamao Y, Yamamoto T, Hirata T, Kinugasa M, Kimumoto M. ffect of argipidine (MD-805) on blood coagulation. Jpn Phaimacol Ther 1986; 14: 869-874
    PubMedGoogle Scholar
  • 33 Mamyama I. ynthetic anticoagulants. Jpn J Clin Hematol 1990; 31: 776-781
    PubMedGoogle Scholar
  • 34 Yonekawa Y, Handa H, Okamoto S, Kamijo Y, Oda Y, Ishikawa J, Tsuda H, Shimizu Y, Satoh M, Yamaguchi T, Yano I, Horikawa Y, Tsuda E. reatment of cerebral infarction in the acute stage with synthetic antithrombin MD805 Clinical study among multiple institutions. Arch Jpn Chir 1986; 55: 711-726
    PubMedGoogle Scholar
  • 35 Kumon K, Tanaka K, Nakajima N, Naito Y, Fijuta T. nticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med 1984; 12: 1039-1043
    CrossrefPubMedGoogle Scholar
  • 36 Oshiro T, Kanbayashi J, Kosaki G. ntithrombotic therapy of patient with peripheral arterial reconstruction-clinical study on MD805. Blood & Vessel 1983; 14: 216-218
    CrossrefPubMedGoogle Scholar
  • 37 Matsuo T, Kario K, Kodama K, Okamoto S. linical applications of the synthetic thrombin inhibitor, Argatroban (MD-805). Sem Thromb Hemost 1992; 18 (02) 155-160
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Bang NU, Mattler LMattler. hrombin sensitivity and specificity of three chromogenic peptide substrates. p305-310. In: Chemistry and Biology of thrombin. Lundblad RL, Fenton JW, Mann KG. eds. Ann Arbor Science. Ann Arbor, MI: 1977
    Google Scholar
  • 39 Fareed J, Messmore HL, Kindel G, Balis JBalis. nhibition of serine proteases by low molecular weight peptides and their derivatives. NY Acad Sci 1981; 370: 765-784
    CrossrefPubMedGoogle Scholar
  • 40 Bajusz S, Barabas E, Szell E, Bagdy D. eptide aldehyde inhibitors of the fibrinogen-thrombin reaction. In: Peptides - Chemistry, Structure and Biology. Meienhofer J. ed. Ann Arbor Sci. Publ. Inc.m; Ann Arbor, MI: 1975: 603-608
    Google Scholar
  • 41 Bajusz S, Barabas E, Tolnay P, Szell E, Bagdy D. nhibition of thrombin and trypsin by tripeptide aldehydes. Int J Peptide Protein Res 1978; 12: 217-221
    PubMedGoogle Scholar
  • 42 Bajusz S, Szell E, Bagdy D, Barabas E, Dioszegi M, Fittler Z, Josza F, Horvath G, Tomori E. US Patent No. 4,703,036,, 1987
    PubMed
  • 43 Bajusz S, Szell E, Bagdy D, Barabas E, Horvath E, Dioszegi M, Fittler Z, Szabo G, Juhasz A, Tomori E, Szilagyi G. ighly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe- Pro-Arg-H. J Med Chem 1990; 33: 1729-1735
    CrossrefPubMedGoogle Scholar
  • 44 Bagdy D, Barabas E, Bajusz S, Szell E. n vitro inhibition of blood coagulation by tripeptide aldehydes -a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H4LS04 . Throm Hemost 1992; 67 (03) 325-330
    PubMedGoogle Scholar
  • 45 Kettner C, Shaw E. he selective inactivation of thrombin by peptides of chloromethyl ketone, pi29-144. In: Chemistry and Biology of thrombin. Lundblad RL, Fenton JW, Mann KG. eds. Ann Arbor Science. Ann Arbor, MI: 1977
    Google Scholar
  • 46 Stiiber W, Kosina H, Heimburger N. ynthesis of a tripeptide with a C- terminal moiety and the inhibition of proteinases. Int J Peptide Protein Res 1988; 31: 63-70
    PubMedGoogle Scholar
  • 47 Neises B, Tamus C. hrombin inhibition by the tripeptide trifluoromethyl ketone D-Phe-Pro-Arg-CF3 (MDL73756). ThrombHaemost 1991; 65: 1290
    PubMedGoogle Scholar
  • 48 Cheng L, Scully MF, Goodwin CA, Kakkar VV, Claeson G. eptide a- aminophosphonic acids. A new type of thrombin inhibitors. Thromb Haemost 1991; 65: 1289
    PubMedGoogle Scholar
  • 49 Kettner C, Mesinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-18297
    PubMedGoogle Scholar
  • 50 Tapparelli C, Mettemich R, Ehrhardt C, Zurinin M, Claeson G, Scully MF, Stone SStone. n vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268 (07) 4734-4741
    PubMedGoogle Scholar
  • 51 Kaiser B, Farced J, Hoppensteadt D, Birdsong B, Walenga JM, Markwardt F. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thromb Res 1992; 65 (02) 157-164
    CrossrefPubMedGoogle Scholar
  • 52 Kaiser B, Callas D, Hoppensteadt D, Malinowska K, Fareed J. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on the generation of thrombin and factor Xa generation in biochemically defined systems. Thromb Res 1994; 73 (05) 327-335
    CrossrefPubMedGoogle Scholar
  • 53 Fareed J, Walenga JM, Kumar A, Rock A. modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 227-236
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerkus AL, Hirsh J. comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: the influence on the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar